NCT06832540View on ClinicalTrials.gov

Mass Balance Study of [14C] TJ0113 in Healthy Chinese Subjects

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 19, 2025

Primary Completion Date

March 5, 2025

Study Completion Date

August 15, 2025

Conditions
Healthy Chinese Subjects
Interventions
DRUG

[14C]TJ0113

Subjects will receive a single oral dose of approximately 200 mg/100 μCi of the oral formulation of \[14C\] TJ0113 under fasted conditions.

Trial Locations (1)

Unknown

Affiliated Hospital of Jiangnan University, Wuxi

All Listed Sponsors
lead

Hangzhou PhecdaMed Co., Ltd.

INDUSTRY

NCT06832540 - Mass Balance Study of [14C] TJ0113 in Healthy Chinese Subjects | Biotech Hunter | Biotech Hunter